Secukinumab Therapeutic Cheat Sheet
Secukinumab is a recombinant human monoclonal immunoglobulin IgG1κ antibody that selectively targets interleukin-17A (IL-17A), a key effector cytokine in the Th17 pathway implicated in the pathogenesis of psoriasis. With its high target specificity, rapid onset, sustained efficacy, and favorable safety profile, secukinumab has become a mainstay in the treatment of psoriasis and other inflammatory …
Secukinumab is a recombinant human monoclonal immunoglobulin IgG1κ antibody that selectively targets interleukin-17A (IL-17A), a key effector cytokine in the Th17 pathway implicated in the pathogenesis of psoriasis. With its high target specificity, rapid onset, sustained efficacy, and favorable safety profile, secukinumab has become a mainstay in the treatment of psoriasis and other inflammatory … 
A First-Time Attendee’s Experience at ODAC 2025: A Conference Worth Attending
As a first-time attendee at the 2025 ODAC Dermatology Conference, I was beyond impressed with my experience. From the expertly curated sessions to the invaluable networking opportunities, ODAC delivered an immersive and engaging educational experience. If you are considering attending in the future, let me assure you� … 
Health recently wrote an article detailing laser hair removal as a treatment option for hidradenitis suppurativa (HS). What role does laser hair removal play in an HS treatment plan, and which patients make good candidates? For an expert’s perspective, I reached out to Steven Daveluy, MD, FAAD, professor and program director at Wayne State Dermatology.
In your practice, what role does laser hai … 